3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

06/16/2026, 3:30 AM • The Motley Fool

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics announced clinical trial results for ribupatide, a GLP-1/GIP receptor dual agonist in development as both an oral pill and weekly injection for obesity treatment. Phase 2 oral data showed mean weight loss of up to 12.1% with 38.6% of participants achieving 15% weight loss at 26 weeks, with low gastrointestinal side effects. Phase 1 injection data demonstrated similar safety and efficacy across Asian and non-Asian populations. Both companies plan to advance to Phase 3 trials, with global oral trials potentially starting in H1 2027.

06/05/2026, 7:32 PM • GlobeNewswire

Is Kailera Therapeutics a Buy After Its Sizzling IPO?

Kailera Therapeutics (KLRA) went public on April 17, 2026, pricing at $16 and opening at $26 per share, positioning itself as a competitor in the obesity treatment market. The company has a promising pipeline of weight-loss drug candidates, including its lead candidate Ribupatide in phase 3 trials. While the GLP-1 market could reach $190 billion by 2035, investing in Kailera remains high-risk as the company has no approved commercial products yet.

05/16/2026, 10:30 AM • The Motley Fool

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

Kailera Therapeutics, a spinoff of Hengrui Pharma's weight-loss drug portfolio, surged 63% on its Nasdaq debut, validating the 'NewCo' business model where Chinese drugmakers spin off promising pipelines into standalone companies. The IPO raised $625 million, the largest by a Chinese pharma company using this strategy. Hengrui retains a 9.8% stake now valued at ~$300 million and benefits from milestone payments and royalties.

04/23/2026, 12:08 PM • Benzinga

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kailera Therapeutics, Inc. (NASDAQ: KLRA), a clinical-stage biotechnology company focused on obesity care, announced the successful closing of its IPO on April 20, 2026. The company offered 44.9 million shares at $16.00 per share, including the full exercise of underwriters' option for 5.9 million additional shares, generating gross proceeds of $718.8 million. The offering was led by J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and William Blair.

04/20/2026, 4:05 PM • Benzinga